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Background and Purpose: Although the presence of cavitating lacunes on brain imaging
may have prognostic implications, the modifiable risk factors underlying these frequently
observed lesions are not completely understood. We sought to determine if fasting and
post-challenge triglycerides associate with cavitating lacunes.
Methods: All first ischemic stroke patients who completed a novel combined oral triglyc-
eride and glucose tolerance test and MRI between January 2009 and June 2012 were
included. Fluid-attenuated inversion recovery or T2 MRI sequences were used to visualize
cavitating lacunes and white matter hyperintensities, which were graded using theWahlund
visual scale.
Results:One hundred and ninety patients were included (median age 66, IQR 52–73; 33%
female; median National Institute of Health Stroke Scale 2, IQR 1–4). A forward stepwise
binary logistical regression analysis applying the Hosmer–Lemeshow goodness of fit test
adjusted for parameters significant in univariate analyses (at the p<0.10 level) revealed
thatWahlund scores (Wahlund 0–4: reference;Wahlund 5–10: adjusted odds ratio, 5.1; 95%
confidence interval, 1.3–20.0, p=0.019; Wahlund >10: adjusted odds ratio 9.6; 95% CI,
1.55–59.35; p=0.015) and the highest quartile of post-challenge triglycerides (>295 mg/dL;
adjusted odds ratio, 7.36; 95% confidence interval 1.24–43.70; p=0.028) independently
associated with the presence of cavitating lacunes.
Conclusion: Post-challenge serum triglycerides are independently associated with the
presence of cavitating lacunes.
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INTRODUCTION
Although cavitating lacunes (small, deep 3–20 mm cerebrospinal
fluid containing “holes”) (1) often appear “silently” (without
stroke-like symptoms) on brain imaging (2), their presence is
thought to more than double the risk of stroke and dementia (3).
Age and hypertension are two established risk factors for cavitating
lacunes (2–4), but evidence suggests that elevated serum triglyc-
erides may also be a key factor in cavitating lacune development
and progression (2).
Postmortem findings support the hypothesis that triglycerides
play a role in cavitating lacunes. First, histopathology studies have
identified fat-laden macrophages surrounding the small vessels in
areas of cavitating lacunes (5) similar to that of the lipid-laden
monocytes observed in the “fatty streak” of muscular arteries
affected by atherosclerosis (6). It has been proposed that prolonged
exposure to elevated triglycerides alters endothelial metabolism
and expression of binding molecules thereby predisposing for
monocyte aggregation and forming the nidus of a “fatty streak”
(7). Second, studies have determined that vessels supplying cav-
itating lacunes are frequently affected by “lipohyalinosis” (fatty
hyaline build-up within the vessel wall), a specific subgroup of the
broader “small vessel disease” term (8).
Elevated triglycerides have long been suspected of being a mod-
ifiable cerebrovascular risk factor (9–11), however findings from
studies that have measured fasting triglycerides have yielded con-
flicting results (12). Traditionally measured in the fasting state to
avoid variability, more recent findings from large epidemiologi-
cal studies (with over 10,000 participants) indicate that post-fat
challenge triglyceride levels may be a more reliable indicator of
cardiovascular and in particular ischemic stroke risk than fasting
levels (10, 11). This has led to the recommendation of possi-
bly introducing a standardized oral triglyceride tolerance test to
clinical practice (13).
We therefore sought to determine if an association exists
between fasting and post-challenge triglyceride levels and cavi-
tating lacunes.
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MATERIALS AND METHODS
PARTICIPANTS
The Berlin “Cream & Sugar” Study (NCT 01378468) is an ongoing
prospective cohort study that aims to assess the prognostic impact
of post-challenge triglyceride and glucose levels in ischemic stroke
patients. Detailed methods and inclusion/exclusion criteria are
presented elsewhere (14). Briefly, we screened all male and female
first-time acute ischemic stroke patients (3–7 days after symptom
onset) over 18 years of age, who were admitted to one of three
university campus hospitals in Berlin. Ischemic stroke was defined
as a focal neurological deficit lasting for at least 24 h with no signs
of hemorrhage on cerebral imaging. First ever ischemic stroke was
defined here using relevant medical history and disregarded poten-
tial “silent” strokes on cerebral imaging that may have occurred
prior to study enrollment. All suspected ischemic strokes were
verified radiologically using diffusion-weighted images (DWI).
Stoke was categorized according to a mechanism-based classifi-
cation scheme (Trial of ORG 10172 in Acute Stroke Treatment,
or TOAST) (15). All patients provided informed consent and the
study was approved by the local ethics committee.
Stroke severity was assessed 3–7 days after first ischemic stroke
using the National Institute of Health Stroke Scale (NIHSS).
ORAL TRIGLYCERIDE TOLERANCE TEST
Fasting blood samples were drawn at 8 a.m. Directly thereafter,
patients drank 250 mL of 32% fat cream within 30 min in the
presence of a Center for Stroke Research Berlin staff member to
ensure that the cream was ingested. Three hours later (11 a.m.), a
second blood draw was performed and was immediately followed
by a standard 75 g oral glucose tolerance test. Subsequent blood
draws were then performed at 12 p.m. and 1 p.m.
BLOOD SAMPLES
Baseline data and venous blood samples were collected after par-
ticipants had provided informed consent and fasted overnight
for ≥12 h. Fasting blood samples were drawn at 8 a.m. Triglyc-
eride and cholesterol concentrations were determined in freshly
drawn venous blood samples enzymatically using a Cobas 6000
analyzer (Roche/Hitachi). Glomerular filtration rate (GFR) was
estimated using the Modification of Diet in Renal Disease
(MDRD) (16) formula according to relationship 186× serum
creatinine−1.154× age−0.203× 1.210 (if Black)× 0.742 (if female).
Diabetes was defined as current use of antidiabetic medication,
serum glycosylated hemoglobin (HbA1C) of >6.5% or 2 h oral
glucose tolerance test value of >200 mg/dL. Hypertension was
defined as current antihypertensive medication use. Hyperlipi-
demia was defined as fasting total cholesterol≥200 mg/dL and/or
fasting triglycerides ≥150 mg/dL and/or use of lipid lowering
medications prior to ischemic stroke (17).
IMAGE ACQUISITION, CAVITATING LACUNES, ANDWMH SEVERITY
MRI was performed using both 3 T (Tim Trio; Siemens AG, Erlan-
gen, Germany) and 1.5 T (Avanto, Siemens Medical Solutions,
Erlangen, Germany) scanners. Patients who were admitted to
one of three university campus hospitals underwent “Fast Track”
Stroke MRI that consisted of DWI, T1, T2∗, and either FLAIR or
T2 weighted images (depending on the campus hospital). FLAIR
or T2 weighted images were used to assess cavitating lacunes and
white matter hyperintensity (WMH) severity. Because different
campus hospitals utilized different MRI scanners (3 and 1.5 T),
sensitivity of MRI field strength to detect lacunes and WMH was
tested using Fischer’s exact (lacune presence) and Mann–Whitney
U tests (non-stratified Wahlund scores).
White matter hyperintensity were scored according to the Age-
Related White Matter Change (18) and Fazekas (19) visual classi-
fication systems (Figure 1). In the Wahlund classification system,
FLAIR and T2 image hyperintensities are rated from 0 to 3 based
on size and confluence of the lesions on both the right and left
sides of the brain in the following pre-specified regions: frontal,
parieto-occipital, temporal, infratentorial/cerebellum, and basal
ganglia. The final score is the sum of all regions and ranges from
0 (no WMH) to 30 (most severe WMH). In the Fazekas classifi-
cation system, the image with the most severe WMH is rated on
a scale of 0 to 3 [0, no WMH; 1, punctate foci; 2, beginnings of
confluent foci; 3 large confluent areas; (19)].
Cavitating lacunes were defined as small (3–20 mm in all direc-
tions) hypointense lesions on FLAIR and hyperintense lesions
on T2 weighted images with a corresponding low intensity area
on T1 weighted images (Figure 1) (1, 20). Cavitating lacunes
were identified as ovoid/spheroid shaped areas with similar sig-
nal intensity to that of cerebrospinal fluid generally (on FLAIR
images) surrounded by a hyperintense rim (2). Because Virchow–
Robin spaces also have similar signal intensity to cerebrospinal
fluid, we differentiated cavitating lacunes from Virchow–Robin
spaces based on size [cavitating lacunes: 3–20 mm;Virchow–Robin
spaces smaller than 3 mm and generally following a vessel; (2)]. We
recorded both presence of cavitating lacunes (present versus not
present) and the number of cavitating lacunes observed in each
patient.
STATISTICAL ANALYSIS
Continuous variables were tested for normal distribution using
the Kolmogorov–Smirnov test. Mann–Whitney U tests were used
to examine relationships between baseline and serum parameters
(not normally distributed) and lacunes (present or not present).
The relationship between categorical variables (gender, hyperten-
sion, smoking history, and diabetes mellitus), lacunes, and WMH
severity was assessed using two-sided Fisher’s exact tests. If a sig-
nificant relationship was found, post hoc analyses using Sidak’s
method were performed (level of significance at 0.017). To esti-
mate odds ratios in the categorical analysis, Wahlund scores were
stratified into 3 groups: mild (Wahlund score of 0–4), moderate
(Wahlund: 5–10), and severe (Wahlund:>10), as this classification
(21, 22) and very similar stratification schemes have been used
previously (23, 24) and seem to correspond well with standard
visual classification systems (23). Spearman’s correlation coeffi-
cients were calculated to assess relationships between number of
lacunes and baseline/serum parameters.
We performed a forward stepwise binary logistical regres-
sion analysis using the Hosmer–Lemeshow goodness of fit test.
This analysis included all parameters associated with cavitat-
ing lacunes (at the p< 0.10 level) from univariate analyses and
the dichotomized categorical variable cavitating lacunes (present
versus not present). Serum glucose, glycosylated hemoglobin,
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FIGURE 1 | Fluid attenuated inversion recovery (FLAIR) MRI
sequences of (A) a 21 year old patient with an overallWahlund score
of 0, (B) a 51 year old patient with an overallWahlund score of 8, (C)
a 69 year old patient with aWahlund score of 20, (D) a 75 year old
man with an overallWahlund score of 12 and a 4mm cavitating
lacune in the left parietal lobe, (E) a 63 year old man with an overall
Wahlund score of 5 and a 5.5mm cavitating lacune in the right
occipito-temporal region, (F) a 70 year old man with an overall
Wahlund score of 20 and an 4mm cavitating lacune in the left
pareito-temporal region.
creatinine, C-reactive protein, waist circumference, waist-to-hip
ratio, and systolic blood pressure were not normally distributed
and were stratified into quartiles. Age was categorized by decades
starting at age 18 years and ending at age 101 years to incorpo-
rate all patients enrolled in our study. All statistical analyses were
performed using SPSS 19.
RESULTS
We enrolled 211 patients in the Berlin “Cream & Sugar” study
between January 2009 and June 2012. Of those, 190 patients
(median age 66, IQR 52–73; 33% female; median NIHSS 2, IQR
1–4) had both MRI (148 FLAIR, 42 T2) and serum parameters
available. All strokes were confirmed on MRI.
Results from univariate analyses and patient demographics
for cavitating lacunes are presented in Table 1. Patients who
had more cavitating lacunes were older (Spearman’s rho= 0.118,
p= 0.042), more likely to have higher post-challenge glucose lev-
els (Spearman’s rho= 0.121, p= 0.050), and had higher Wahlund
(Spearman’s rho= 0.305, p< 0.01) and Fazekas scores (Fischer’s
exact,p< 0.01).Post hoc testing revealed that patients with Fazekas
scores of 2 and 3 had significantly more lacunes than patients
with Fazekas scores of 1 (Fazekas 2: p= 0.031, 95% confidence
interval 0.15–0.40; Fazekas 3: p< 0.01, 95% confidence interval
0.15–0.68). Although the associations did not reach significance,
patients with more cavitating lacunes tended to have higher glyco-
sylated hemoglobin (HbA1c, Spearman’s rho= 0.117, p= 0.054).
In patients with HbA1c values <6.5%, elevated absolute 5 h
post-challenge triglycerides significantly associated with lacune
presence (p= 0.006) and number of lacunes (p= 0.019). More-
over, in patients with HbA1c values <6.5%, higher triglyceride
area under the curve significantly associated with lacune presence
(p= 0.032). Number of lacunes, however, was not significantly
associated with triglyceride area under the curve in these patients
(p= 0.134).
Presence and number of lacunes and WMH did not signifi-
cantly differ in patients rated with FLAIR versus T2 images (Fis-
cher’s exact test: lacune presence, p= 0.66; number of lacunes,
p= 0.68; WMH, p= 0.39). Comparisons across patients accord-
ing to MRI strength (3 versus 1.5 T) revealed that those patients
who received 3 T MRI scans (N = 95) were rated as having signifi-
cantly more WMH than those scanned with a 1.5 T MRI (N = 94;
p< 0.01). Dichotomized presence (present versus not present) and
absolute number of cavitating lacunes did not differ according to
MRI field strength (Exact Mann–Whitney U, cavitating lacune
presence, p= 0.89; Exact Mann–Whitney U, number of cavitating
lacunes, p= 0.589).
A forward stepwise binary logistical regression using the
Hosmer–Lemeshow goodness of fit test that was adjusted for
age (decades), NIHSS scores, fasting and post-challenge triglyc-
erides and glucose, glycosylated hemoglobin, waist-to-hip ratio,
and WML (Wahlund and Fazekas scores) revealed that WML (both
Wahlund and Fazekas) scores and the highest quartile of post-
challenge triglycerides independently associated with presence of
cavitating lacunes (Table 2).
DISCUSSION
The primary findings of this study were that elevated post-
challenge serum triglycerides (>3.33 mmol/L) and WMH sever-
ity independently associated with cavitating lacunes. To our
knowledge, this is the first study that has assessed the rela-
tionship between fasting and post-challenge serum triglyc-
erides and pre-existing cavitating lacunes in acute ischemic
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Table 1 | Demographic characteristics according to presence of cavitating lacunes.
No lacunes Lacunes Total pValue
No. of participants 156 34 190
Female, n (%)* 55 (30) 6 (3) 61 (33) 0.065
Age, year† 63 (51–72) 70 (61–75) 66 (52–73) 0.035
Hypertension, n (%)* 76 (48) 20 (13) 96 (61) 0.286
Hyperlipidemia, n (%)* 83 (48) 25 (15) 108 (63) 0.109
Current smokers, n (%)* 29 (19) 7 (5) 36 (23) 0.274
Diabetes, n (%)* 20 (13) 6 (4) 26 (17) 0.411
Wahlund score† 4 (1–5) 8 (3–11) 3 (1–6) <0.01
NIHSS† 1 (0–2) 2 (0–3) 1 (0–2) 0.269
eGFR† 83 (72–100) 76 (69–96) 82 (71–98) 0.416
Creatinine, µmol/L† 79 (67–89) 85 (65–98) 80 (67–90) 0.272
Systolic BP† 130 (120–150) 140 (120–150) 135 (120–150) 0.601
Diastolic BP† 80 (70–87) 80 (70–85) 80 (70–86) 0.739
BMI, kg/m2† 26 (23–29) 26 (25–29) 26 (24–29) 0.759
LDL (mg/dL)† 110 (91–137) 112 (81–136) 110 (90–137) 0.558
CRP (mg/dL)† 0.3 (0.1–0.7) 0.2 (0.1–0.8) 0.3 (0.1–0.7) 0.696
HbA1c, %† 5.6 (5.2–6.1) 5.8 (5.5–6.2) 5.6 (5.3–6.1) 0.033
Waist-to-hip ratio† 0.96 (0.92–1.0) 0.98 (0.94–1.03) 0.97 (0.92–1.0) 0.092
Fasting Glc (mmol/L)† 5.3 (4.8–6.0) 5.7 (4.7–6.7) 5.3 (4.8–6.1) 0.220
3 h Glc (mmol/L)† 5.1 (4.8–5.7) 5.4 (4.9–6.6) 5.2 (4.8–5.8) 0.052
4 h Glc (mmol/L)† 7.2 (5.6–9.2) 7.8 (6.0–10.4) 7.3 (5.7–9.4) 0.271
Fasting TG (mmol/L)† 1.2 (0.9–1.6) 1.4 (1.1–1.7) 1.2 (1.0–1.6) 0.098
5 h TG (mmol/L)† 2.3 (1.7–3.1) 3.0 (1.8–3.9) 2.4 (1.7–3.4) 0.080
Values are median (interquartile range) unless otherwise specified.
NIHSS indicates National Institute of Health Stroke Scale; mRS, modified Rankin Scale; eGFR, estimated glomerular filtration rate; BP, blood pressure; LDL, low
density lipoprotein; CRP, C-reactive protein; HbA1c, glycosylated hemoglobin; Glc, glucose; TG, triglycerides.
*Fischer’s exact test followed by Sidak’s post hoc method (if significant).
†Mann–Whitney U test.
Table 2 | Results from forward stepwise binary logistical regression
analysis assessing risk factors for cavitating lacunes.
Predictors OR 95% CI pValue
Wahlund score 0–4 Reference
Wahlund score 5–10 5.101 1.30–20.02 0.019
Wahlund score >10 9.600 1.55–59.36 0.015
Fazekas score 0–1 Reference
Fazekas score 2 4.777 1.26–18.09 0.021
Fazekas score 3 6.932 1.06–45.45 0.044
TG <1.73 mmol/L Reference
TG 1.73–2.36 mmol/L 0.547 0.07–4.59 0.578
TG 2.36–3.33 mmol/L 1.736 0.24–12.61 0.586
TG >3.33 mmol/L 7.358 1.24–43.70 0.028
Odds ratios are adjusted for age (decades), NIHSS scores, fasting and post-
challenge triglycerides and glucose, glycosylated hemoglobin, waist-to-hip ratio,
and Wahlund and Fazekas scores.
CI indicates confidence interval; OR, odds ratio; ref, reference; TG, triglycerides.
stroke patients. Previous studies have found a relationship
between non-fasting triglycerides and risk of ischemic stroke
and heart disease (10, 11, 25). Our findings are similar in
that post-challenge triglycerides independently associated with
the presence of cavitating lacunes but fasting triglycerides
did not.
Triglyceride concentrations rose markedly in all patients follow-
ing the fat challenge. Interestingly, all patients showed very similar
increases in triglyceride concentrations following the challenge
until the 5 h post-challenge time-point, an occurrence that others
have also observed (26). Groot et al. (26) measured triglyceride
concentrations for 24 h following an oral fat challenge and noted
that elevated triglycerides measured at the 8 h time-point or later
were indicative of increased common carotid artery intima-media
thickness. Though not statistically significant in their study (26),
graphical representation showed that triglyceride levels began to
diverge between those patients with and without carotid artery
atherosclerosis at the 5 h time-point. Though our study was a rela-
tively small retrospective sub-analysis, these findings could suggest
that time to triglyceride “clearance” may play a role in cerebrovas-
cular risk and that blood draws between 5 and 8 h post-challenge
may be optimal for triglyceride analysis. Additionally, results from
our univariate analysis indicate that a triglyceride tolerance test
may be of particular benefit for the assessment of vascular risk
in patients without diabetes mellitus. Further testing is needed to
verify these finding.
Pathophysiologically, “silent” cavitating lacunes are thought to
arise from deep cortical ischemia (5, 27, 28). A recent literature
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review concluded that the risk of ischemic stroke onset nearly
doubles if cavitating lacunes are present on MRI (3). We found that
post-challenge triglycerides associated with cavitating lacunes and
others have identified a strong independent association between
non-fasting triglycerides and ischemic stroke risk (10, 11). Taken
together, it is possible that cavitating lacunes mark high stroke
risk patients who may be identifiable in a cost-effective manner
by measuring non-fasting triglycerides and even possibly bene-
fited by triglyceride lowering strategies (life style modification or
medication).
Our results conflict with those of Gouw et al. (2), who assessed
possible risk factors for lacune progression (in 396 patients) and
found that elevated fasting triglycerides and body mass index
(BMI) were associated with the appearance of new cavitating
lacunes. We found that obesity indices (BMI and waist-to-hip
ratio) associated with WMH and both fasting and non-fasting
triglycerides (data not shown) but, unlike Gouw et al. obesity
indices did not correspond with the presence of cavitating lacunes.
We expected obesity indices to associate with cavitating lacunes,
as cavitating lacunes associated with non-fasting triglycerides and
WMH. However, it is likely that our study was underpowered to
detect these relationships, as there were only 34 participants with
cavitating lacunes.
We focused on cavitating lacunes (as opposed to non-cavitating
lacunes or a combination of the two) for the sake of simplicity as
there is currently much debate regarding terminology. Because it
remains unclear which lacunes will cavitate and which will not (or
perhaps all cavitate after a certain time), the recommendation has
been put forth to independently examine cavitating lacunes and
WMH (which might be an early form of lacune that has not yet
cavitated or something else altogether) and their respective risk
factors (29). Our results show that WMH severity independently
associates with the presence of cavitating lacunes, thus lending cre-
dence to the argument that though the exact etiologies of WMH
and cavitating lacunes may differ, it is difficult to disaggregate the
two (29). Moreover, this association may support the hypothesis
that cavitating lacunes are simply a more pronounced form of
WMH (29).
A distinction has been made between: (1) single, larger, symp-
tomatic lacunar infarcts of microatheromatous origin and (2)
small, multiple, typically asymptomatic lacunar infarcts (generally
accompanying WMH) possibly of arteriolosclerosis origin (30).
None of our patients reported “stroke-like symptoms” before the
event leading to hospital admission and cerebral imaging was per-
formed in the acute stroke setting. Because cavitation seems to
occur slowly – taking well over a month post-insult for complete
cavitation to occur in most cases (31) – and WMH associated with
presence of lacunes so strongly, we believe the cavitating lacunes
present in our patient sample likely arose from arterioloscle-
rotic (small vessel disease) origin rather than microatheromatous
origin.
Our study has limitations. First, because this was a Berlin
“Cream & Sugar”substudy, there was a selection bias toward mildly
affected stroke patients (median NIHSS at hospital admission 2,
range 0–24; median NIHSS at time of fat challenge 1, range 0–14).
This resulted from the Berlin “Cream & Sugar” study’s relatively
stringent inclusion criteria, as only those patients who: (1) were
deemed capable of completing and tolerating a novel combined
oral triglyceride/glucose tolerance test (i.e., patients without swal-
lowing disorders, lactose intolerance, malabsorption, etc.) and (2)
who did not have pre-existing conditions that could potentially
influence lipid metabolism (liver disease, alcoholism, pancreatic
disease, etc.) were selected. Second, the cohort was comprised pri-
marily of older patients (median 66 years), which has been well
established to associate with cavitating lacunes (3) and increased
WMH severity (18). Third, women were underrepresented (33%).
We therefore recommend a cautious interpretation of the observed
trend across gender (Table 1) and lacune presence. Fourth, because
we pooled patients that were admitted to various hospitals and
scanned with different MRI field strengths (3 and 1.5 T), it is pos-
sible that lacunes and WMH were underreported. However, results
from the logistical regression analysis did not change after we ret-
rospectively controlled for MRI field strength. Finally, our cohort
was relatively small (190 patients). We decided to use a forward
stepwise algorithm for data analysis to minimize possible compli-
cations arising from low covariate incidence rates. However, larger
studies are needed to assess the validity of our findings.
In conclusion, we assessed fasting and post-challenge triglyc-
eride levels in acute ischemic stroke patients with and without
pre-existing cavitating lacunes and found that elevated post-
challenge triglycerides were associated with the presence of cav-
itating lacunes. Patients with elevated non-fasting triglycerides
may be at a higher risk for cerebral ischemia and therefore bene-
fit from triglyceride lowering strategies (life style modification or
medication).
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